Solventum (SOLV) PT Raised to $84 at Piper Sandler

Piper Sandler analyst Jason Bednar raised the price target on Solventum (NYSE: SOLV) to $84.00 (from $75.00) while maintaining a Neutral rating.

The analyst commented: "SOLV reported 4Q results that included revenue ($2,074M/+2.3% organic) and EPS ($1.41) that came in above consensus as the SOLV team extends its early track record of quarterly beats. Management also provided initial 2025 guidance, which includes +1%-2% organic growth and EPS of $5.45-$5.65, each a hair above where investor expectations had settled in recent weeks. Additional P&F sale details also leave us comfortable the net impact of the transaction will be accretive in 2026, but even more critical from this move is the pull-forward in financial flexibility we believe it provides management for internal or external reinvestment. That's all fairly positive in the context of expectations (which is important), but we're sticking with our Neutral rating due to organic growth that seems likely to remain in LSD territory near-term and margin improvement that may not materialize in a meaningful way until late '25 at the earliest. PT to $84."

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
• Cosa Resources announces C$5 million bought deal private placement